0.3360SEK+1.82%Mkt Cap: 102.17M SEKP/E: —Last update: 2026-05-13
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of Am…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-0.34
PEG—
P/B0.96
P/S9.35
EV/EBITDA-0.26
EV/Revenue1.72
EPS (TTM)-0.42
EPS (Forward)-1.04
Cash Flow & Leverage
FCF Yield-38.47%
FCF Margin-359.77%
Operating CF-85.37M SEK
CapEx (TTM)287.00K SEK
Net Debt/EBITDA1.14
Net Debt-83.39M SEK
Technical
SMA 500.3415 (-1.6%)
SMA 2000.4748 (-29.2%)
Beta1.09
S&P 52W Chg24.23%
Avg Vol (30d)315.06K
Avg Vol (10d)326.98K
Technical Indicators
RSI (14)48.8
MACD-0.0041
MACD Signal-0.0055
MACD Hist.+0.0014
BB Upper0.3645 SEK
BB Middle0.3353 SEK
BB Lower0.3061 SEK
BB Width17.42%
ATR (14)0.0342 SEK
Vol Ratio (20d)0.13x
52W Range
0.27007% of range1.180
52W High1.180 SEK
52W Low0.2700 SEK
Profitability
Gross Margin93.79%
EBITDA Margin0.00%
Profit Margin-1016.52%
Oper. Margin-543.14%
ROE-202.81%
ROA-134.91%
Revenue Growth45.70%
Earnings Growth—
Balance Sheet
Debt/Equity0.11
Current Ratio5.42
Quick Ratio5.30
Book Value/Sh0.3630 SEK
Cash/Share0.3020 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.277.49M
Float252.32M
Insiders0.00%
Institutions0.01%
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)0.7000 SEK
Target Range0.7000 SEK – 0.7000 SEK
# Analysts1
Company
Market Cap102.17M SEK
Enterprise Value18.78M SEK
Revenue (TTM)10.93M SEK
Gross Profit8.09M SEK
Net Income (TTM)-87.62M SEK
Revenue/Share0.0590 SEK
Fiscal Year EndApr 2025
MR QuarterJan 2026
Employees24
Last Price0.3360 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—